Testing if the drug letrozole reaches brain tumors in people with a glioma that came back
Original title: Study of Letrozole in Recurrent Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study checks whether a drug called letrozole can get into a brain tumor.
Who this trial is for. This trial is for people with a glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has come back. It tests whether letrozole can cross into the brain and build up in the tumor.
Where it stands. The trial has not reported results. It is measuring how much letrozole reaches the brain and the tumor. That answer is not in yet.
What this means, and what it doesn't
What it could mean: The study is asking a basic first question: can this drug even reach the tumor. Knowing that helps researchers decide what to try next. Someone who fits the study might ask their care team about it.
What it doesn't mean: This does not mean letrozole treats glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. A trial is a test, not a proven treatment. Being in one does not promise any benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.